Physician profile
John Dunn
NPI 1124128046
$18,485.94
in general payments reported to CMS, 2019-2025
75 companies · $59.34 in 2025
The $59.34 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,888 · 2020: $1,790 · 2021: $3,996 · 2022: $3,186 · 2023: $4,010 · 2024: $2,557 · 2025: $59.34.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,143 · Long Term Medical Supply Or Device Loan: $250 · Education: $234.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,142.59 |
| Long Term Medical Supply Or Device Loan | $249.99 |
| Education | $234.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,691.09 | 2019-2024 | |
| Incyte Corporation | $1,008.41 | 2019-2025 | Monjuvi, Jakafi, Pemazyre |
| Genentech USA, INC. | $968.33 | 2019-2024 | Tecentriq, Lunsumio, Polivy |
| Amgen INC. | $889.90 | 2019-2022 | |
| Astellas Pharma US INC | $821.68 | 2019-2024 | Padcev, Xtandi, Xospata |
| E.R. Squibb & Sons, L.L.C. | $816.21 | 2019-2024 | Opdivo, Opdualag |
| Janssen Biotech, INC. | $776.72 | 2019-2024 | Tecvayli, Darzalex, Erleada |
| Pfizer INC. | $736.05 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $639.15 | 2019-2024 | Keytruda, Lynparza, Welireg |
| Regeneron Healthcare Solutions, INC. | $613.96 | 2019-2024 | Libtayo |
| Astrazeneca Pharmaceuticals LP | $566.85 | 2019-2024 | Lynparza, Calquence, Enhertu |
| Daiichi Sankyo INC. | $520.43 | 2020-2024 | Enhertu |
| Celgene Corporation | $458.02 | 2019-2024 | Pomalyst, Reblozyl, Opdualag |
| Abbvie INC. | $405.67 | 2019-2024 | Venclexta |
| Seagen INC. | $326.43 | 2020-2023 | Padcev, Tukysa, Adcetris |
Show all 75 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $312.23 | 2019-2024 | Verzenio, Jaypirca, Retevmo |
| Takeda Pharmaceuticals U.S.A., INC. | $312.11 | 2019-2024 | Ninlaro, Alunbrig, Iclusig |
| Gilead Sciences, INC. | $311.67 | 2019-2024 | Trodelvy |
| Glaxosmithkline, LLC. | $287.89 | 2019-2024 | Ojjaara, Zejula, Jemperli |
| Eisai INC. | $272.56 | 2019-2024 | |
| Beigene USA, INC. | $272.56 | 2020-2024 | Brukinsa |
| Bayer Healthcare Pharmaceuticals INC. | $266.34 | 2019-2023 | |
| Genzyme Corporation | $240.29 | 2019-2024 | |
| Heron Therapeutics, INC. | $233.61 | 2021 | |
| Pharmacyclics LLC, An Abbvie Company | $219.52 | 2020-2023 | Imbruvica |
| Eagle Pharmaceuticals, INC. | $207.66 | 2024 | |
| Exelixis INC. | $200.28 | 2019-2023 | Cabometyx |
| Genmab U.S., INC. | $182.91 | 2023-2024 | Epkinly |
| Boehringer Ingelheim Pharmaceuticals, INC. | $161.49 | 2019-2023 | Gilotrif |
| Ipsen Biopharmaceuticals, INC | $145.34 | 2019-2024 | Onivyde, Somatuline Depot |
| Deciphera Pharmaceuticals INC. | $139.60 | 2020-2023 | Qinlock |
| Aveo Pharmaceuticals, INC. | $137.70 | 2023-2024 | Fotivda |
| Array Biopharma INC | $132.84 | 2019-2024 | Lorbrena, Xalkori, Braftovi |
| Blueprint Medicines Corporation | $125.41 | 2020-2024 | |
| Taiho Oncology, INC. | $123.61 | 2019-2024 | |
| Coherus Oncology, INC. | $110.38 | 2021-2023 | |
| Clovis Oncology, INC. | $109.13 | 2019-2020 | |
| Pharmaessentia USA Corporation | $95.14 | 2023 | Besremi |
| Myovant Sciences INC. | $93.75 | 2021-2022 | |
| Kite Pharma, INC. | $92.82 | 2020-2023 | Yescarta |
| Karyopharm Therapeutics INC. | $91.95 | 2020-2024 | Xpovio |
| Janssen Pharmaceuticals, INC | $81.96 | 2019-2022 | |
| Rigel Pharmaceuticals, INC. | $77.78 | 2019-2024 | Rezlidhia, Tavalisse |
| Puma Biotechnology, INC. | $76.98 | 2019-2024 | Nerlynx |
| Acceleron Pharma, INC. | $76.25 | 2020-2021 | |
| Adaptive Biotechnologies Corporation | $71.96 | 2023-2024 | Clonoseq |
| Morphosys, US INC. | $71.89 | 2022-2023 | Monjuvi |
| Dendreon Pharmaceuticals LLC | $66.02 | 2019-2024 | Provenge |
| Spectrum Pharmaceuticals INC. | $59.08 | 2023-2024 | Rolvedon |
| Acrotech Biopharma INC. | $59.00 | 2021-2024 | Beleodaq |
| Servier Pharmaceuticals LLC | $58.78 | 2021-2024 | |
| Pharmacosmos Therapeutics INC. | $58.71 | 2022-2023 | Monoferric |
| Tesaro, INC. | $55.02 | 2019 | |
| Alexion Pharmaceuticals, INC. | $53.28 | 2023-2024 | Ultomiris, Soliris |
| Emd Serono, INC. | $48.25 | 2020-2024 | |
| G1 Therapeutics, INC. | $38.71 | 2022-2023 | Cosela |
| Jazz Pharmaceuticals INC. | $36.01 | 2020-2023 | |
| Progenics Pharmaceuticals, INC. | $35.56 | 2022-2024 | |
| Hema Biologics, LLC | $33.60 | 2023 | Sevenfact |
| Adc Therapeutics America, INC. | $33.34 | 2022-2024 | |
| Kyowa Kirin, INC. | $32.02 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $30.49 | 2023 | Orgovyx |
| Verastem, INC. | $25.33 | 2019-2020 | |
| Tersera Therapeutics LLC | $23.38 | 2023 | Quzyttir |
| Agios Pharmaceuticals, INC. | $20.01 | 2024 | Pyrukynd |
| Epizyme, INC. | $19.12 | 2022 | |
| Stemline Therapeutics INC. | $18.26 | 2024 | Orserdu |
| Global Blood Therapeutics, INC. | $15.02 | 2020 | |
| Innate Pharma, INC | $14.58 | 2020 | |
| Sirtex Medical INC | $14.15 | 2020 | |
| Amag Pharmaceuticals, INC. | $13.74 | 2021 | |
| Foundation Medicine, INC. | $13.32 | 2021 | |
| Mirati Therapeutics, INC. | $13.30 | 2023 | Krazati |
| Lexicon Pharmaceuticals, INC. | $11.83 | 2020 | |
| Secura Bio, INC. | $11.52 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Dunn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.